HER4 expression in estrogen receptor-positive breast cancer is associated with decreased sensitivity to tamoxifen treatment and reduced overall survival of postmenopausal women
- Standort
-
Deutsche Nationalbibliothek Frankfurt am Main
- ISSN
-
1465-542X
- Umfang
-
Online-Ressource
- Sprache
-
Englisch
- Anmerkungen
-
online resource.
- Erschienen in
-
HER4 expression in estrogen receptor-positive breast cancer is associated with decreased sensitivity to tamoxifen treatment and reduced overall survival of postmenopausal women ; volume:20 ; number:1 ; day:20 ; month:11 ; year:2018 ; pages:1-15 ; date:12.2018
Breast cancer research ; 20, Heft 1 (20.11.2018), 1-15, 12.2018
- Urheber
-
Wege, Anja Kathrin
Chittka, Dominik
Buchholz, Stefan
Klinkhammer-Schalke, Monika
Diermeier-Daucher, Simone
Zeman, Florian
Ortmann, Olaf
Brockhoff, Gero
- Beteiligte Personen und Organisationen
-
SpringerLink (Online service)
- DOI
-
10.1186/s13058-018-1072-1
- URN
-
urn:nbn:de:101:1-2019010400305914901285
- Rechteinformation
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Letzte Aktualisierung
-
14.08.2025, 10:52 MESZ
Datenpartner
Dieses Objekt wird bereitgestellt von:
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Beteiligte
- Wege, Anja Kathrin
- Chittka, Dominik
- Buchholz, Stefan
- Klinkhammer-Schalke, Monika
- Diermeier-Daucher, Simone
- Zeman, Florian
- Ortmann, Olaf
- Brockhoff, Gero
- SpringerLink (Online service)
Ähnliche Objekte (12)
Raptor localization predicts prognosis and tamoxifen response in estrogen receptor-positive breast cancer
Predicting prognosis using molecular profiling in estrogen receptor-positive breast cancer treated with tamoxifen
Nogo-B receptor increases the resistance to tamoxifen in estrogen receptor-positive breast cancer cells
Targeting c-Jun inhibits fatty acid oxidation to overcome tamoxifen resistance in estrogen receptor-positive breast cancer
Sex-steroid hormones and risk of postmenopausal estrogen receptor-positive breast cancer: a case–cohort analysis
BreastDefend enhances effect of tamoxifen in estrogen receptor-positive human breast cancer in vitro and in vivo
CYP27A1 expression is associated with risk of late lethal estrogen receptor-positive breast cancer in postmenopausal patients
Small molecule inhibitor targeting the Hsp70-Bim protein–protein interaction in estrogen receptor-positive breast cancer overcomes tamoxifen resistance
Genomic alterations identified by array comparative genomic hybridization as prognostic markers in tamoxifen-treated estrogen receptor-positive breast cancer
Molecular markers associated with the outcome of tamoxifen treatment in estrogen receptor-positive breast cancer patients: scoping review and in silico analysis
Local estrogen axis in the human bone microenvironment regulates estrogen receptor-positive breast cancer cells
The impact of CBP expression in estrogen receptor-positive breast cancer
Raptor localization predicts prognosis and tamoxifen response in estrogen receptor-positive breast cancer
Predicting prognosis using molecular profiling in estrogen receptor-positive breast cancer treated with tamoxifen
Nogo-B receptor increases the resistance to tamoxifen in estrogen receptor-positive breast cancer cells
Targeting c-Jun inhibits fatty acid oxidation to overcome tamoxifen resistance in estrogen receptor-positive breast cancer
Sex-steroid hormones and risk of postmenopausal estrogen receptor-positive breast cancer: a case–cohort analysis
BreastDefend enhances effect of tamoxifen in estrogen receptor-positive human breast cancer in vitro and in vivo
CYP27A1 expression is associated with risk of late lethal estrogen receptor-positive breast cancer in postmenopausal patients
Small molecule inhibitor targeting the Hsp70-Bim protein–protein interaction in estrogen receptor-positive breast cancer overcomes tamoxifen resistance
Genomic alterations identified by array comparative genomic hybridization as prognostic markers in tamoxifen-treated estrogen receptor-positive breast cancer
Molecular markers associated with the outcome of tamoxifen treatment in estrogen receptor-positive breast cancer patients: scoping review and in silico analysis
Local estrogen axis in the human bone microenvironment regulates estrogen receptor-positive breast cancer cells
The impact of CBP expression in estrogen receptor-positive breast cancer
Raptor localization predicts prognosis and tamoxifen response in estrogen receptor-positive breast cancer
Predicting prognosis using molecular profiling in estrogen receptor-positive breast cancer treated with tamoxifen
Nogo-B receptor increases the resistance to tamoxifen in estrogen receptor-positive breast cancer cells
Targeting c-Jun inhibits fatty acid oxidation to overcome tamoxifen resistance in estrogen receptor-positive breast cancer
Sex-steroid hormones and risk of postmenopausal estrogen receptor-positive breast cancer: a case–cohort analysis
BreastDefend enhances effect of tamoxifen in estrogen receptor-positive human breast cancer in vitro and in vivo
CYP27A1 expression is associated with risk of late lethal estrogen receptor-positive breast cancer in postmenopausal patients
Small molecule inhibitor targeting the Hsp70-Bim protein–protein interaction in estrogen receptor-positive breast cancer overcomes tamoxifen resistance
Genomic alterations identified by array comparative genomic hybridization as prognostic markers in tamoxifen-treated estrogen receptor-positive breast cancer
Molecular markers associated with the outcome of tamoxifen treatment in estrogen receptor-positive breast cancer patients: scoping review and in silico analysis
Local estrogen axis in the human bone microenvironment regulates estrogen receptor-positive breast cancer cells